Cargando…

A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma

Cisplatin-based concurrent chemoradiotherapy for patients with unresectable, locally advanced esophageal squamous cell carcinoma (ESCC) is associated with significant toxicities that are often intolerable. Prognosis for this subgroup of patients remains poor, and new therapeutic approaches are urgen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Chuanhua, Lin, Li, Liu, Jianzhi, Liu, Rongrui, Chen, Yuling, Ge, Feijiao, Jia, Ru, Jin, Yang, Wang, Yan, Xu, Jianming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302991/ https://www.ncbi.nlm.nih.gov/pubmed/28087951 http://dx.doi.org/10.18632/oncotarget.9809

Ejemplares similares

Is There a Benefit in Receiving Concurrent Chemoradiotherapy for Elderly Patients with Inoperable Thoracic Esophageal Squamous Cell Carcinoma?
por: Zhang, Peng, et al.
Publicado: (2014)

Endostatin and Oxaliplatin‐Based Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Results of a Phase II Study
por: Li, Wenxin, et al.
Publicado: (2019)

Long‐term outcome of concurrent chemoradiotherapy with elective nodal irradiation for inoperable esophageal cancer
por: Jing, Zhao, et al.
Publicado: (2017)

The Modified Glasgow Prognostic Score Is an Independent Prognostic Factor in Patients with Inoperable Thoracic Esophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy
por: Zhang, Peng, et al.
Publicado: (2014)

A combined immune prognostic index in esophageal squamous cell carcinoma patients treated with anti-PD-1 therapy
por: Ji, Shoujian, et al.
Publicado: (2023)

Postoperative Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial
por: Li, Hui, et al.
Publicado: (2022)

A Retrospective Comparison of Taxane and Fluorouracil-based Chemoradiotherapy in Patients with Inoperable Esophageal Squamous Cell Carcinoma
por: Sun, Xiaojiang, et al.
Publicado: (2016)

Endoscopic debulking resection with additive chemoradiotherapy: Optimal management of advanced inoperable esophageal squamous cell carcinoma
por: Ren, Li-Hua, et al.
Publicado: (2022)

Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
por: Zhou, Xi-Lei, et al.
Publicado: (2021)

Consolidation Chemotherapy Rather than Induction Chemotherapy Can Prolong the Survival Rate of Inoperable Esophageal Cancer Patients Who Received Concurrent Chemoradiotherapy
por: Xia, Xiaojie, et al.
Publicado: (2022)

Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients
por: Chen, Chih-Yi, et al.
Publicado: (2018)

Definitive concurrent chemoradiotherapy with paclitaxel plus carboplatin is superior to cisplatin plus 5‐fluorouracil in patients with inoperable esophageal squamous cell carcinoma using retrospective, real‐world evidence
por: Hsieh, Jason Chia‐Hsun, et al.
Publicado: (2021)

Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma
por: Qiu, Xiangnan, et al.
Publicado: (2020)

Clinical efficacy evaluation of Erlotinib Combined with Concurrent Chemoradiotherapy in the treatment of locally advanced Pancreatic Cancer
por: Liu, Ci, et al.
Publicado: (2022)

Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study
por: Liu, Chengxin, et al.
Publicado: (2023)

Cardiac Dose Predicts the Response to Concurrent Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
por: Ho, Yu-Chieh, et al.
Publicado: (2023)

Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial
por: Liu, Shiliang, et al.
Publicado: (2021)

A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of the pharynx or larynx
por: Huang, Pei-Wei, et al.
Publicado: (2018)

Single‐Agent Versus Double‐Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial
por: Zhao, Zhenhuan, et al.
Publicado: (2020)

Sequential boost of intensity‐modulated radiotherapy with chemotherapy for inoperable esophageal squamous cell carcinoma: A prospective phase II study
por: Fan, Xing‐Wen, et al.
Publicado: (2020)

Low cardiac dose and neutrophil-to-lymphocyte ratio predict overall survival in inoperable esophageal squamous cell cancer patients after chemoradiotherapy
por: Ho, Yu-Chieh, et al.
Publicado: (2021)

Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604)
por: Tahara, Makoto, et al.
Publicado: (2015)

Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial
por: Li, Hui, et al.
Publicado: (2022)

Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma
por: Shi, Zhenguo, et al.
Publicado: (2022)

Prognosis impact of clinical characteristics in patients with inoperable esophageal squamous cell carcinoma
por: Yang, Ying, et al.
Publicado: (2017)

Effectiveness of image‐guided radiotherapy for locally advanced esophageal squamous cell carcinoma patients treated with definitive concurrent chemoradiotherapy
por: Kuo, Yao‐Hung, et al.
Publicado: (2019)

A Meta-Analysis of Concurrent Chemoradiotherapy for Advanced Esophageal Cancer
por: Zhu, Li-Li, et al.
Publicado: (2015)

Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck
por: Kim, J G, et al.
Publicado: (2005)

Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy
por: Zhou, Xi‐Lei, et al.
Publicado: (2019)

GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma
por: Tsou, Yung-Kuan, et al.
Publicado: (2017)

Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study
por: Kato, Ken, et al.
Publicado: (2018)

Chemotherapy alone versus definitive concurrent chemoradiotherapy for cT4b esophageal squamous cell carcinoma: a population-based study
por: Li, Chia-Chin, et al.
Publicado: (2021)

Optimal radiotherapy dose in cervical esophageal squamous cell carcinoma patients treated with definitive concurrent chemoradiotherapy: A population based study
por: Li, Chia‐Chin, et al.
Publicado: (2021)

Consolidative chemotherapy after definitive concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients: a population based cohort study
por: Lin, Chen-Yuan, et al.
Publicado: (2022)

Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study
por: Liu, Rongrui, et al.
Publicado: (2021)

A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma
por: Ni, Wenjie, et al.
Publicado: (2020)

Systemic Immune-Inflammatory Index, Tumor-Infiltrating Lymphocytes, and Clinical Outcomes in Esophageal Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy
por: Yang, Jun, et al.
Publicado: (2023)

Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer
por: Noh, Jae Myoung, et al.
Publicado: (2015)

The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy
por: Shim, Hyun-Jeong, et al.
Publicado: (2016)

Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma
por: Park, Sehhoon, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i38v2at4umd4lmna795b5qajr9